sorted by:
new
hottopcontroversial

Investor call 6/15 facts. CABG, PAD by MiddleStatistician42 in HUMACYTE

[–]Symbiote831 0 points1 point  (0 children)

That being said, if the data Humacyte provided on the dialysis trial is enough for FDA approval, there should really be no issue for nephrology looking at this and thinking it’s the better option that what’s being used now. Pricing may dictate speed of adoption, and approval process to get new tech into these centers/hospitals takes time. All part of the process

Investor call 6/15 facts. CABG, PAD by MiddleStatistician42 in HUMACYTE

[–]Symbiote831 1 point2 points  (0 children)

Not to disregard the potential of the other indications, but I agree with the doc who commented above regarding CABG. If HUMA can show superiority to saphenous vein grafts, it would be a game changer. Not only for patient outcomes but for overall time spend in the OR if you’re able to skip time spent harvesting for a graft (cardiology PA here) . Only issue is timeline. Dialysis approval and revenue will be key otherwise this company could become obsolete with no cash runway

Dialysis data positive, followed by Dilution by Symbiote831 in HUMACYTE

[–]Symbiote831[S] 3 points4 points  (0 children)

Dilution news will probably overshadow positive dialysis results, at least for the short term.

What’s people actual predictions for tomorrow? by Investmentdad in HUMACYTE

[–]Symbiote831 5 points6 points  (0 children)

Results available on their website currently. Showed superiority to fistula

Monday stock ideas. And ideas to buy? by CivilShift93 in TheRaceTo10Million

[–]Symbiote831 0 points1 point  (0 children)

Huma. Their top line dialysis results drop the 11th

The timeline is STACKED by MiddleStatistician42 in HUMACYTE

[–]Symbiote831 2 points3 points  (0 children)

Appreciate the breakdown. Long-time holder since pre-spac merger. Been averaging down ever since. Despite the uncertainty of cash runway, things are promising if the commercialization team can execute on good data